Trials / Withdrawn
WithdrawnNCT04289428
Evaluation of Novel Point of Care Hepatitis B Diagnostic Assays
- Status
- Withdrawn
- Phase
- —
- Study type
- Observational
- Enrollment
- 0 (actual)
- Sponsor
- Kirby Institute · Other Government
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Evaluation of novel point of care Hepatitis B diagnostic assays.
Detailed description
This study aims to evaluate the sensitivity of the following novel assays for evaluation of HBV infection and assessment of treatment eligibility; * GeneXpert HBV DNA via Fingerstick testing, * Dried Blood Spot based HBV DNA * Point of care ALT.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Xpert® HBV DNA fingerstick point of care assay | Xpert® HBV DNA point of care assay from finger-stick whole blood |
| DIAGNOSTIC_TEST | Point of Care ALT | Point of Care ALT from finger-stick whole blood |
| DIAGNOSTIC_TEST | Xpert® HBV DNA point of care assay from dried blood spot | Xpert® HBV DNA point of care assay from dried blood spot |
Timeline
- Start date
- 2022-01-01
- Primary completion
- 2022-07-01
- Completion
- 2022-10-01
- First posted
- 2020-02-28
- Last updated
- 2021-12-03
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT04289428. Inclusion in this directory is not an endorsement.